Objective
To evaluate the prognostic performance of a new biomarker, plasma bioactive adrenomedullin (bio-ADM), for short-term clinical outcomes in acute heart failure.
Methods
A multicenter prospective cohort study of adult emergency department (ED) patients suspected of having acute heart failure was conducted to evaluate the association between plasma bio-ADM concentration and clinical outcomes. The primary outcome was a composite of the following within 30 days: death, cardiac arrest with resuscitation, respiratory failure, emergency dialysis, acute coronary syndrome, hospitalization >5 days, and repeat ED visit or hospitalization. Prognostic accuracy was evaluated with a non-parametric receiver operating characteristic (ROC) curve. Additionally, a multivariable logistic regression model was constructed to assess the additive prognostic performance of bio-ADM while adjusting for other biomarkers routinely used clinically, including BNP, cardiac troponin I, creatinine, and sodium concentration.
Results
Two hundred forty-six patients were enrolled, including 85 (34.6%) patients with the primary outcome. Plasma bio-ADM concentrations were higher among patients who experienced the primary outcome (median: 80.5 pg/ml; IQR: 53.7 pg/ml, 151.5 pg/ml) compared to those who did not (median: 54.4 pg/ml; IQR: 43.4 pg/ml, 78.4 pg/ml) (p < 0.01). Area under the ROC curve was 0.70 (95% CI: 0.63, 0.75). After adjusting for the other biomarkers, plasma bio-ADM remained a strong predictor of the primary outcome (adjusted odds ratio per IQR change: 2.68; 95% CI: 1.60, 4.51).
Conclusions
Bio-ADM concentrations at the time of ED evaluation for acute heart failure were predictive of clinically-important 30-day outcomes, suggesting bio-ADM is a promising prognostic marker for further study.